Neurobiology and Experimental Treatment of TBI Pain and Anxiety
TBI 疼痛和焦虑的神经生物学和实验治疗
基本信息
- 批准号:8426001
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-01 至 2016-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAmygdaloid structureAnimalsAnxietyBehaviorBehavioralBrain regionCell NucleusCervicalChronicCognitionCognitiveCommunity ServicesCraniocerebral TraumaDevelopmentDorsalExerciseFunctional disorderHeadHealthcare SystemsHippocampus (Brain)ImmuneImpaired cognitionInflammationInjuryInterventionLesionMagnetismMass Spectrum AnalysisMeasuresModelingMorbidity - disease rateNeurobiologyNeurologicNeurologic ManifestationsNeuronsNorepinephrineOutcomeOutcome MeasurePainRattusSeveritiesSocietiesSpinalSystemTBI treatmentTestingTherapeuticTimeTranslationsTraumatic Brain InjuryTreatment EfficacyUp-RegulationVeteransbasedisabilityeffective interventiongray matterimmunocytochemistryinterestknowledge basemultiple disabilitynoradrenergicpregabalinprogramssafety testing
项目摘要
DESCRIPTION (provided by applicant):
Closed head traumatic brain injury (CH-TBI) results in a broad spectrum of neurological deficits. Recently, those involving cognition, pain sensitivity, and anxiety, have risen to the level of urgency for the development of new information that can enhance therapy for CH-TBI. This study proposes a unifying hypothesis regarding the multiple-morbidity that frequently following CH-TBI. It proposes that that dysfunction of the central noradrenergic (NA) system is a common underlying denominator of these multiple disabilities. Four aims are proposed to investigate specific neurological deficits induced by CH-TBI, how these are correlated with noradrenergic injury, and the potential for these deficits to be modified by three treatments that target upregulation of the central noradrenergic system. A fifth aim proposes a proof of principle sudy. Aim 1 will determine the severity and time-course of the three neurological manifestations following mild/moderate CH-TBI in a rat head injury model. Aims 2 will correlate the magnitude of behavioral changes after CH-TBI with measures of NA expression in regions of the brain predominantly involved in the specific behaviors of interest (i.e., hippocampus CA1 and CA3, central nucleus of the amygdala, and cervical and lumbar dorsal spinal gray matter). The third Aim will test the safety, feasibility, and efficacy of three therapies - activity wheel locomotor (AWL) exercise, transcortical magnetic stimulation (TMS), and pregabalin alone or in combination - on cognitive, pain, and anxiety outcomes of mild and moderate CH-TBI. Aim 4 will examine how these treatments affect regional NA expression using mass spectrometry and norepinephrine (NE) immunocytochemistry. Aim 5 will further test the central hypothesis by evaluating treatment efficacy (using the best treatment combination) in animals following selective immune-lesion of central noradrenergic neurons. The proposed studies will increase our knowledge base of: 1) CH-TBI-induced cognitive dysfunctions, anxiety, pain disabilities, and chronic inflammation; 2) the relationship of these disabilities with dysregulation of the central NA system; 3) the value of specific treatments to decrease the severity of long term disabilities; and 4) the impact of therapeutic program to significantly alter central NA levels and decrease the magnitude of CH-TBI-induced chronic inflammation. Translation of these findings may provide safe, timely, and effective intervention strategies which can significantly benefit the veterans' health care system.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PRODIP K. BOSE其他文献
PRODIP K. BOSE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PRODIP K. BOSE', 18)}}的其他基金
Preclinical evaluation of efficacy and safety of a new iron chelator therapy in chronic spinal cord injury
新型铁螯合剂疗法治疗慢性脊髓损伤的临床前疗效和安全性评价
- 批准号:
10701817 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Preclinical evaluation of efficacy and safety of a new iron chelator therapy in chronic spinal cord injury
新型铁螯合剂疗法治疗慢性脊髓损伤的临床前疗效和安全性评价
- 批准号:
10536492 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Efficacy and safety of a new hexadentate iron chelator therapy for TBI-induced chronic disabilities in a rodent model
新型六齿铁螯合剂治疗啮齿动物模型中 TBI 引起的慢性残疾的功效和安全性
- 批准号:
10524736 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Efficacy and safety of a new hexadentate iron chelator therapy for TBI-induced chronic disabilities in a rodent model
新型六齿铁螯合剂治疗啮齿动物模型中 TBI 引起的慢性残疾的功效和安全性
- 批准号:
10000779 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Efficacy and safety of a new hexadentate iron chelator therapy for TBI-induced chronic disabilities in a rodent model
新型六齿铁螯合剂治疗啮齿动物模型中 TBI 引起的慢性残疾的功效和安全性
- 批准号:
10268189 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Therapeutic potential of combined locomotor training and TMS in SCI
联合运动训练和 TMS 在 SCI 中的治疗潜力
- 批准号:
8784815 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Neurobiology and Experimental Treatment of TBI Pain and Anxiety
TBI 疼痛和焦虑的神经生物学和实验治疗
- 批准号:
8838164 - 财政年份:2012
- 资助金额:
-- - 项目类别:
Neurobiology and Experimental Treatment of TBI Pain and Anxiety
TBI 疼痛和焦虑的神经生物学和实验治疗
- 批准号:
8840067 - 财政年份:2012
- 资助金额:
-- - 项目类别:
Neurobiology and Experimental Treatment of TBI Pain and Anxiety
TBI 疼痛和焦虑的神经生物学和实验治疗
- 批准号:
8202899 - 财政年份:2012
- 资助金额:
-- - 项目类别: